‘They Need Each Other’: Why Hims & Hers and Novo Nordisk Made Up

Marissa Plescia / medcitynews - Novo Nordisk dropped its lawsuit against Hims & Hers and launched a new collaboration. The deal is advantageous for both companies, experts say.The post ‘They Need Each Other’: Why Hims & Hers and Novo Nordisk Made Up appeared first on MedCity News.

AI Summary: Novo Nordisk has dropped its legal fight with Hims & Hers and struck a business-friendly truce: Hims will sell Novo’s branded weight‑loss medications on its platform. The abrupt move turns courtroom theatrics into commercial collaboration, smoothing distribution while leaving regulators and competitors to enjoy the schadenfreude.

GLP‑1 drugs may fight addiction across every major substance, according to a study of 600,000 people

medicalxpress - A patient of mine, a veteran who had tried to quit smoking for over a decade, told me that after he started a GLP-1 drug for his diabetes, he lost interest in cigarettes. He didn't use a patch. He didn't set a quit date. He simply lost interest. It happen…

AI Summary: A large observational analysis suggests GLP‑1 receptor agonists — the headline-grabbing diabetes and weight-loss drugs — are linked to reduced risk of developing and dying from substance use disorders across multiple substances. Researchers urge cautious optimism: signals are intriguing, but causality remains unproven and more controlled trials are needed before rewriting addiction treatment playbooks.

Novo Nordisk inks $2.1B oral obesity drug deal

Ella Jeffries / beckershospitalreview - Novo Nordisk has partnered with Vivtex Corp. to develop next-generation oral biologic medicines for obesity, diabetes and related conditions. Under the agreement, Vivtex will license its proprietary oral drug-delivery technologies to Novo Nordisk and is e…

AI Summary: Novo Nordisk has struck a multibillion‑dollar deal with Vivtex to develop next‑generation oral biologic therapies for obesity and related metabolic diseases. The partnership funnels major R&D resources into oral delivery technology, signaling the company’s bet that pills — not injections — will be the next commercial battleground in weight‑loss medicine.

Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial

Elizabeth Cairns / endpoints - Novo Nordisk’s GLP-1/amylin combo drug CagriSema was not as good as Eli Lilly’s marketed obesity shot Zepbound in a head-to-head study, the Danish company said Monday. Patients in the REDEFINE 4 ...

AI Summary: In a direct comparator study, Eli Lilly’s marketed obesity drug Zepbound produced greater mean weight loss than Novo Nordisk’s experimental CagriSema. The result complicates the competitive landscape for anti‑obesity medicines and will influence prescribers, payers and the almighty market share tussle.

Novo Nordisk vows legal action to protect Wegovy pill

medicalxpress - Novo Nordisk said Thursday it would take legal action against a US chain offering a copycat of the new pill version of its Wegovy weight-loss drug.

AI Summary: Novo Nordisk has vowed to take legal action after discovering that competitors – including Hims & Hers – plan to market a compounded, lower‐priced version of its new Wegovy weight‐loss pill. The company is mobilizing its legal team to protect its intellectual property amid fierce market competition.

Compounding pharmacy sues Eli Lilly, Novo Nordisk over GLP-1 access

Ella Jeffries / beckershospitalreview - Strive Compounding Pharmacy filed a federal antitrust lawsuit Jan. 14 against Eli Lilly and Novo Nordisk, alleging the two drugmakers used their market power to restrict access to compounded GLP-1 medications and suppress competition. The lawsuit, filed i…

AI Summary: A compounding pharmacy has taken legal aim at industry giants Eli Lilly and Novo Nordisk, alleging an anti‑competitive scheme designed to restrict access to their blockbuster GLP‑1 therapies. The lawsuit puts the pharmaceutical titans on the defensive as antitrust concerns mix with therapeutic access debates.

FDA moves to remove suicide warnings from GLP-1 weight loss drugs

medicalxpress - Federal health regulators say popular weight loss drugs like Wegovy and Zepbound do not increase the risk of suicidal thoughts, and they have asked drugmakers to remove those warnings from medication labels.

AI Summary: In a surprising twist, the FDA has decided that the long‐rumored risk of suicidal ideation on popular GLP‑1 weight‐loss drugs may have been overblown. Regulators have now asked drugmakers – including Lilly and Novo Nordisk – to scrub these warnings from product labels, a move that is sure to spark both relief and raised eyebrows among critics.

Novo Nordisk’s Wegovy Pill Becomes First FDA-Approved Oral GLP-1 Drug for Weight Loss

Frank Vinluan / medcitynews - Beyond weight reduction and long-term maintenance of weight loss, the FDA decision for oral Wegovy covers use of the once-daily pill for reducing the risk of major cardiovascular events. Novo Nordisk expects the Wegovy tablet will launch in early January.…

AI Summary: The FDA has given its nod to Novo Nordisk’s oral GLP‑1 receptor agonist for chronic weight management – a historic first for an anti‑obesity pill. The approval offers patients a non‑injectable alternative, potentially transforming obesity care in a market hungry for innovation.

Novo submits high-dose Wegovy for FDA approval using voucher

Max Bayer / endpoints - Novo Nordisk submitted a higher dose of its obesity drug Wegovy for FDA approval and is using a recently-won voucher to expedite the review. The company said Wednesday that it submitted ...

AI Summary: Novo Nordisk has formally submitted its application to the FDA to approve a higher-dose formulation of its flagship obesity drug, Wegovy. Leveraging a recently secured priority voucher, the filing is set to potentially expand treatment options for weight management as the review process begins.

Novo Nordisk GLP-1 fails to slow Alzheimer’s in trials

Ella Jeffries / beckershospitalreview - Novo Nordisk’s GLP-1 drug semaglutide did not demonstrate a statistically significant effect in slowing progression of Alzheimer’s disease in two late-stage clinical trials. According to a Nov. 24 news release from the company, two double-blinded, placebo…

AI Summary: Novo Nordisk’s much‑talked‑about GLP‑1 drug, famed for its weight‐loss benefits, has hit an unexpected wall in Alzheimer’s trials. In two separate reports – one on the standard injectable and another on a pill form – semaglutide showed no statistically significant impact on slowing brain decline. Who knew obesity meds couldn’t multitask?

Novo Nordisk rolls out lower prices for Ozempic and Wegovy

medicalxpress - People paying out of pocket for Ozempic or Wegovy may soon see lower costs, as Novo Nordisk rolls out new price discounts for its popular GLP-1 medications.

AI Summary: In a bid to ease the financial burden on self‐pay patients, Novo Nordisk has unveiled deep price cuts for its flagship GLP-1 drugs, Ozempic and Wegovy. The new pricing strategy comes amid intensifying market pressures and aims to broaden access to these critical therapies for weight management and type 2 diabetes.

Pfizer’s Sweeter $10B Offer Beats Novo Nordisk in Bidding War for Obesity Biotech Metsera

Frank Vinluan / medcitynews - Pfizer’s offer of up to $86.25 in cash for each share of obesity drugs developer Metsera share tops the up to $86.20 Novo Nordisk was willing to pay. The financial consideration and the greater certainly of a deal close tipped the balance in Pfizer’s favo…

AI Summary: In a dramatic showdown over obesity biotech firm Metsera, Pfizer’s up-to-$10B cash offer edged out Novo Nordisk’s bid. The fiercely competitive deal highlights the high stakes and intense market focus on innovative therapeutics in obesity management.

Pfizer poised to buy Metsera in $10 bn deal after bidding war

medicalxpress - Pfizer was poised to seal a takeover of Metsera on Saturday after its improved offer won over the biotechnology startup's board and Danish challenger Novo Nordisk called a halt to a back-and-forth bidding war.

AI Summary: In a dramatic bidding war for a promising biotech startup, Pfizer’s improved $10 billion offer prevailed—until Novo Nordisk raised its bid yet again. This high-stakes takeover tussle underscores the fierce competition and strategic importance of emerging therapies.

What Trump’s New Drug Pricing Deal Means for People With Obesity

Rebecca Robbins, Dani Blum and Margot Sanger-Katz / nytimes - The president’s agreement with drug companies involves a range of prices, depending on dose, product and how you’re paying.

AI Summary: In a bold move to tackle the obesity crisis, the Trump administration has brokered agreements with industry giants such as Eli Lilly and Novo Nordisk to slash weight-loss drug prices. The deals, promising reductions as steep as $149 a month, have sparked both applause and debate over the future of drug pricing in America.